NCT01831089 - Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Breast CancerOvarian CancerGynecological CancerHead and Neck CarcinomaNon-small Cell Lung CancerSmall Cell Lung CancerNon-squamous Cell Lung Cancer

Interventions

DRUG

PM01183 + paclitaxel +/- bevacizumab

"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"

Trial Locations (3)

Unknown

New York

Madrid

Bellinzona